Enzo Biochem Pre-Tax Profit Margin 2010-2023 | ENZ
Enzo Biochem pre-tax profit margin from 2010 to 2023. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Enzo Biochem Pre-Tax Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Pre-Tax Income |
Pre-Tax Margin |
| 2023-01-31 |
$0.08B |
$-0.04B |
-43.75% |
| 2022-10-31 |
$0.10B |
$-0.03B |
-27.55% |
| 2022-07-31 |
$0.11B |
$-0.02B |
-16.82% |
| 2022-04-30 |
$0.11B |
$-0.01B |
-6.25% |
| 2022-01-31 |
$0.12B |
0 |
0.00% |
| 2021-10-31 |
$0.12B |
$0.01B |
4.31% |
| 2021-07-31 |
$0.12B |
$0.01B |
5.93% |
| 2021-04-30 |
$0.11B |
$0.00B |
0.88% |
| 2021-01-31 |
$0.10B |
$-0.01B |
-11.34% |
| 2020-10-31 |
$0.09B |
$-0.02B |
-24.71% |
| 2020-07-31 |
$0.08B |
$-0.03B |
-38.16% |
| 2020-04-30 |
$0.08B |
$-0.03B |
-40.26% |
| 2020-01-31 |
$0.08B |
$0.00B |
1.25% |
| 2019-10-31 |
$0.08B |
$0.00B |
1.25% |
| 2019-07-31 |
$0.08B |
$0.00B |
3.70% |
| 2019-04-30 |
$0.08B |
$0.00B |
2.41% |
| 2019-01-31 |
$0.09B |
$-0.02B |
-26.14% |
| 2018-10-31 |
$0.10B |
$-0.02B |
-17.89% |
| 2018-07-31 |
$0.10B |
$-0.01B |
-11.88% |
| 2018-04-30 |
$0.10B |
$-0.01B |
-5.83% |
| 2018-01-31 |
$0.11B |
$-0.00B |
-2.86% |
| 2017-10-31 |
$0.11B |
$-0.00B |
-1.90% |
| 2017-07-31 |
$0.10B |
$-0.00B |
-1.92% |
| 2017-04-30 |
$0.11B |
$0.04B |
33.02% |
| 2017-01-31 |
$0.11B |
$0.03B |
31.43% |
| 2016-10-31 |
$0.10B |
$0.04B |
39.42% |
| 2016-07-31 |
$0.10B |
$0.05B |
45.63% |
| 2016-04-30 |
$0.10B |
$0.02B |
18.63% |
| 2016-01-31 |
$0.10B |
$0.02B |
18.00% |
| 2015-10-31 |
$0.10B |
$0.01B |
7.14% |
| 2015-07-31 |
$0.10B |
$-0.00B |
-2.04% |
| 2015-04-30 |
$0.10B |
$-0.01B |
-14.43% |
| 2015-01-31 |
$0.10B |
$-0.01B |
-11.34% |
| 2014-10-31 |
$0.10B |
$-0.01B |
-11.34% |
| 2014-07-31 |
$0.10B |
$-0.01B |
-10.42% |
| 2014-04-30 |
$0.09B |
$-0.01B |
-11.70% |
| 2014-01-31 |
$0.09B |
$-0.02B |
-18.28% |
| 2013-10-31 |
$0.09B |
$-0.02B |
-20.65% |
| 2013-07-31 |
$0.09B |
$-0.02B |
-21.28% |
| 2013-04-30 |
$0.10B |
$-0.05B |
-46.39% |
| 2013-01-31 |
$0.10B |
$-0.04B |
-42.00% |
| 2012-10-31 |
$0.10B |
$-0.04B |
-38.83% |
| 2012-07-31 |
$0.10B |
$-0.04B |
-38.83% |
| 2012-04-30 |
$0.10B |
$-0.02B |
-14.42% |
| 2012-01-31 |
$0.10B |
$-0.01B |
-13.46% |
| 2011-10-31 |
$0.10B |
$-0.02B |
-15.53% |
| 2011-07-31 |
$0.10B |
$-0.01B |
-12.62% |
| 2011-04-30 |
$0.10B |
$-0.02B |
-14.85% |
| 2011-01-31 |
$0.10B |
$-0.02B |
-17.17% |
| 2010-10-31 |
$0.10B |
$-0.02B |
-21.43% |
| 2010-07-31 |
$0.10B |
$-0.02B |
-22.68% |
| 2010-04-30 |
$0.10B |
$-0.02B |
-21.65% |
| 2010-01-31 |
$0.10B |
$-0.02B |
-21.88% |
| 2009-10-31 |
$0.09B |
$-0.02B |
-20.21% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.121B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
